of dividends.Other muni CEF's are also rising, especially PML . VKI is up but not as much. I also own those two. Sentiment ..... the money after the sale. I don't think I would redeploy in PML or VKI at current prices. The only reason I am selling (maybe
From the PIMCO website for PML (except I added the dates): PML , NII = $0.47, UNII= $0.47(1), Distribution ..... difference between six mo average and current. CEFConnect has PML underearning as of 5/31/2014. Comments appreciated
Looking at a number of charts ( PML ) it looks like muni cefs are about to break out to the upside.
start this, but Mrs. Cod has told me to "get that portfolio STUFF out of the dining room!" so before I put it away: Muni: PML , NEV*, VKI Pref: HPS*, JPS*, FPF Other: KYN, PCM, PDI, PFL, PFN, PCI, PCN, PKO, DSL, DMO, BGH *positions
other recent changes in this category -- none) Munis ( 8% of total portfolio): KTF, MMU, MYD, BBK, NEV, BSD, BFK, PML (recent changes in this category -- none) Preferred ( 2% of total portfolio): JPI (sold a little), HPS (sold majority
Considering KTF and NEV, forum favorites. I have noticed KTF down 8 days in a row, and it is on my short list of possibles, thinking it may have a better relative value. Already own PML . Opinions on adding to Muni CEFs at this time? TIA, Rick
22 PFN. Mult. 9.10. 8.82 PCN. Mult. 8.38. 8.47 ESD. Gl/EM. 8.21 7.64 EHI. Gl/EM. 9.79. 8.10 PML . Muni. 6.60. 6.10 BFK. Muni. 6.44. 6.14 HIX. Junk. 9.53. 8.48 My conclusions: 1) CEFs may not end up tanking
discrepency in reporting: pko -.33 vs. market's -.14 pcn -.07 vs. market's +.04 pty -.11 vs. markets's +.02 pml -.04 vs. markets's +.03 I can't think of what is going on. Any ideas? The rest of my holdings match w/ the market
Oct 22 (Reuters) - Biogen Idec Inc said on Wednesday sales of its big-selling new multiple sclerosis drug Tecfidera fell short of Wall Street's lofty expectations, and the company confirmed a serious...
previous forecast of almost $3.2 billion in global sales of the drug this year. In addition, Biogen reported the first case of PML in a Tecfidera patient, who died after complications from pneumonia. We don't think this changes the risk profile of the